



# FibroMeter™



**Noninvasive**  
blood testing for  
the **evaluation** and  
**management** of  
liver fibrosis

**ARUP**<sup>®</sup> LABORATORIES



>150,000

Biopsies performed in the United States\*

~\$300,000,000

Healthcare costs in the United States\*

\$2,000

Average cost per liver biopsy

\* Yearly estimates are based on Medicare and private payer claims data (Definitive Healthcare).

FibroMeter may help reduce costly and invasive liver biopsies.

## FibroMeter <sup>VIRUS</sup>

FibroMeter Virus is specifically designed for patients with chronic viral hepatitis (B, C) with or without HIV coinfection.

### Features and Benefits

- High diagnostic accuracy confirmed by a rules-based expert system to detect discordant results
- No interference in specimens collected from patients with Gilbert disease or hemolysis (e.g., induced by ribavirin)
- Enhanced graphical reporting available

### Biomarkers Measured

- Platelets, alpha-2-macroglobulin, ALT, AST, GGT, prothrombin index, and urea

### Results Provided

- |                          |   |
|--------------------------|---|
| <b>Calculated Scores</b> | Score ranges from 0 to 1 (1 being the most severe stage):   |
|                          | <ul style="list-style-type: none"> <li>• Fibrosis score (FibroMeter)</li> <li>• Cirrhosis score (CirrhoMeter)</li> <li>• Activity score (InflaMeter)</li> </ul> |

- |                                |  |
|--------------------------------|--|
| <b>Metavir Classifications</b> | Corresponding classifications are reported together with the scores:   |
|                                | <ul style="list-style-type: none"> <li>• F0–F4 for fibrosis/cirrhosis</li> <li>• A0–A3 for activity grade</li> </ul> |

### Specimen and Information Required

- 3 mL serum and 1 mL citrated plasma
- Platelet count performed on EDTA whole blood

## FibroMeter <sup>NAFLD</sup>

FibroMeter NAFLD (nonalcoholic fatty liver disease) assesses the stage of liver fibrosis in patients with metabolic steatosis.

### Biomarkers Measured

- Platelets, ALT, AST, glucose, and ferritin

### Specimen and Information Required

- 3 mL serum and 1 mL citrated plasma
- Platelet count performed on EDTA whole blood

# Accurate, Reproducible Results

**FibroMeter** outperforms other noninvasive assessments of liver fibrosis by utilizing an expert system to detect anomalous profiles and maximize diagnostic reliability. While liver biopsy remains the reference method for managing patients with chronic liver disease, noninvasive assessment with FibroMeter can help triage patients and reduce the number of biopsies.

	≥F2	F4
AUROC	0.85–0.89	0.91
Sensitivity %	80.5–89.0	94.1
Specificity %	84.1–89.9	87.6
PPV %	82.0–86.3	68.0
NPV %	77.6–82.5	94.7

Leroy V, et al. *Clin Biochem* 2008, and Cales P, et al. *Hepatology* 2005.

## FibroMeter™

	FibroMeter	Liver Biopsy
<b>Nature of Test</b>	Noninvasive	Invasive
<b>Advantages</b>	Measures global fibrosis, suitable for serial observations	Direct, evaluates coexisting pathologies
<b>Limitations</b>	Indirectly measures functional liver changes	Sampling error, interobserver variability, possible hospitalization
<b>Risks</b>	Very little risk	Pain, bleeding, pneumothorax, hemothorax, infection
<b>Cost</b>	Less expensive than biopsy	Expensive
<b>Contraindications</b>	None known	Uncooperative patient, severe coagulopathy, extrahepatic biliary obstruction, ascites, morbid obesity


For more information, visit  
[aruplab.com/fibrometer](http://aruplab.com/fibrometer)

# References


1. Cales P, et al. A novel panel of blood markers to assess the degree of liver fibrosis. *Hepatology*. 2005;42:1373–81.
2. Leroy V, et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. *Clin Biochem*. 2008;41(16–17):1368–76.
3. Naveau S, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. *Hepatology*. 2009;49:97–105.
4. Cales P, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. *J Hepatology*. 2009;50:165–73.
5. Cales P, et al. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. *Liver Int*. 2010;30:1346–54.
6. Degos, et al. Diagnostic accuracy of FibroScan® and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). *J Hepatology*. 2010;53:1013–21.
7. Zarski JP, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. *J Hepatology*. 2012;56:55–62.
8. Leroy V, et al. Prospective evaluation of FibroTest®, FibroMeter™, and Hepascore® for staging fibrosis in chronic hepatitis B: comparison with hepatitis C. *J Hepatology*. 2014;61(1):28–34.
9. Boursier J, et al. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. *Aliment Pharmacol Ther*. 2014;40(2):178–88.
10. Cales P, et al. Improved fibrosis staging by elastometry and blood test in chronic hepatitis C. *Liver Int*. 2014;34(6):907–17.
11. Cacoub P, et al. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study. *J Hepatology*. 2008;48(5):765–73.
12. Wu SD, et al. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. *World J Gastroenterol*. 2010;16(4):501–7.
13. Bonnard P, et al. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. *Am J Trop Med Hyg*. 2010;82(3):454–8.
14. Halfon P, et al. Effect of antiviral treatment on serum markers of liver fibrosis in HIV/HCV coinfecting patients: the FibroVic 2 study—ANRS HC02. *Antiviral Therapy*. 2009;14(2):211–9.
15. Nguyen-Khac E, et al. Assessment of asymptomatic liver fibrosis in alcoholic patients using FibroScan: prospective comparison with seven noninvasive laboratory tests. *Aliment Pharmacol Ther*. 2008;28(10):1188–98.
16. Boursier J, et al. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. *Hepatology*. 2012;55(1):58–67.
17. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. *Ann Intern Med*. 2013;158:807–20.

More than  
**100**  
Peer-reviewed  
publications









# FibroMeter™

[aruplab.com/fibrometer](https://aruplab.com/fibrometer)



500 Chipeta Way  
Salt Lake City, UT 84108-1221  
Phone: 800-522-2787  
Fax: 801-583-2712  
[aruplab.com](https://aruplab.com)

© 2021 ARUP Laboratories  
BD-TMC-009, Rev 3, April 2021

*ARUP is a nonprofit enterprise of the University of Utah  
and its Department of Pathology.*

This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.